[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. (2018) 68(1):7-30.
[2] Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. (2016) 66(2):115-32.
[3] Rebecca L, Kimberly D, Ahmedin Jemal. Cancer Statistics, 2017. CA Cancer J Clin. (2017) 67(1):7-30.
[4] Remon J, Steuer C, Ramalingam SS, Felip E. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. Ann Oncol. (2018) 29(suppl_1):i20-i27.
[5] Quoix E, Lena H, Losonczy G, Forget F, Chouaid C, Papai Z, et al. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. Lancet Oncol. (2016) 17(2):212-223.
[6] Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. (2016) 17(3):299-308.
[7] Lewis BC, Shim H, Li Q, Wu CS, Lee LA, Maity A, et al. Identification of putative c-Myc-responsive genes: characterization of rcl, a novel growth-related gene. Mol Cell Biol. (1997) 17(9):4967-78.
[8] Prescott JE, Osthus RC, Lee LA, Lewis BC, Shim H, Barrett JF, et al. A novel c-Myc-responsive gene, JPO1, participates in neoplastic transformation. J Biol Chem. (2001) 276(51):48276-84.
[9] Osthus RC, Karim B, Prescott JE, Smith BD, McDevitt M, Huso DL, et al. The Myc target gene JPO1/CDCA7 is frequently overexpressed in human tumors and has limited transforming activity in vivo. Cancer Res. (2005) 65(13):5620-7.
[10] Cheng C, Zhou Y, Li H, Xiong T, Li S, Bi Y, et al. Whole-Genome Sequencing Reveals Diverse Models of Structural Variations in Esophageal Squamous Cell Carcinoma. Am J Hum Genet. (2016) 98(2):256-74.
[11] Ye L, Li F, Song Y, Yu D, Xiong Z, Li Y, et al. Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer. Int J Cancer. (2018) 143(10):2602-2613.
[12] Martín-Cortázar C, Chiodo Y, Jiménez-P R, Bernabé M, Cayuela ML, Iglesias T, et al. CDCA7 finely tunes cytoskeleton dynamics to promote lymphoma migration and invasion. Haematologica. (2019) pii: haematol.2018.215459.
[13] Rousseaux S, Debernardi A, Jacquiau B, Vitte AL, Vesin A, Nagy-Mignotte H, et al. Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med. (2013) 5(186):186ra66.
[14] Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, Iwakawa R, et al. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res. (2012) 72(1):100–111.
[15] Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, Riegman P, et al. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One (2010) 5(4):e10312.
[16] Tang Z, Li C, Kang B , Gao G , Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses.Nucleic Acids Res. (2017) 45(W1):W98-W102.
[17] Gyorffy B, Surowiak P, Budczies J, Lanczky A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. (2013) 8(12):e82241.
[18] Makimoto G, Hotta K, Kiura K. Recent trends in the treatment of unresectable stage III non-small-cell lung cancer. Respir Investig. (2019) 57(4):330-336.
[19] Der SD 1, Sykes J, Pintilie M, Zhu CQ, Strumpf D, Liu N, et al. Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients. J Thorac Oncol. (2014) 9(1):59-64.
[20] Beer DG 1, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. (2002) 8(8):816–24.
[21] Shi R, Zhang C, Wu Y, Wang X, Sun Q, Sun J, et al. CDCA2 promotes lung adenocarcinoma cell proliferation and predicts poor survival in lung adenocarcinoma patients. Oncotarget. (2017) 8(12):19768-19779.
[22] Adams MN, Burgess JT, He Y, Gately K, Snell C, Zhang SD, et al. Expression of CDCA3 Is a Prognostic Biomarker and Potential Therapeutic Target in Non-Small Cell Lung Cancer. J Thorac Oncol. (2017) 12(7):1071-1084.
[23] Nguyen MH, Koinuma J, Ueda K, Ito T, Tsuchiya E, Nakamura Y, et al. Phosphorylation and activation of cell division cycle associated 5 by mitogen-activated protein kinase play a crucial role in human lung carcinogenesis. Cancer Res. (2010) 70(13):5337-47.
[24] Hayama S, Daigo Y, Yamabuki T, Hirata D, Kato T, Miyamoto M, et al. Phosphorylation and activation of cell division cycle associated 8 by aurora kinase B plays a significant role in human lung carcinogenesis. Cancer Res. (2007) 67(9):4113-22.
[25] López-Lázaro M. The stem cell division theory of cancer. Crit Rev Oncol Hematol. (2018) 123:95-113.
[26] Walker MG. Drug target discovery by gene expression analysis: cell cycle genes. Curr Cancer Drug Targets. (2001) 1(1):73-83.
[27] Hu P, Chen X, Sun J, Bie P, Zhang LD. siRNA-mediated knockdown against NUF2 suppresses pancreatic cancer proliferation in vitro and in vivo. Biosci Rep. (2015) 35(1). pii: e00170.
[28] Liu Q, Dai SJ, Li H, Dong L, Peng YP. Silencing of NUF2 inhibits tumor growth and induces apoptosis in human hepatocellular carcinomas. Asian Pac J Cancer Prev. (2014) 15(20):8623-9.
[29] Shi R, Zhang C, Wu Y, Wang X, Sun Q, Sun J, et al. CDCA2 promotes lung adenocarcinoma cell proliferation and predicts poor survival in lung adenocarcinoma patients. Oncotarget. (2017) 8(12):19768-19779.
[30] Adams MN, Burgess JT, He Y, Gately K, Snell C, Zhang SD, et al. Expression of CDCA3 Is a Prognostic Biomarker and Potential Therapeutic Target in Non-Small Cell Lung Cancer. J Thorac Oncol. (2017) 12(7):1071-1084.
[31] Whitfield ML 1, Sherlock G, Saldanha AJ, Murray JI, Ball CA, Alexander KE, et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol. Biol. Cell. (2002) 13(6):1977-2000.
[32] Wang H, Ye L, Xing Z, Li H, Lv T, Liu H, et al. CDCA7 promotes lung adenocarcinoma proliferation via regulating the cell cycle. Pathol Res Pract. 2019 Nov;215(11):152559.
[33] Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, et al. Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. Cancer Discov. (2016) 6(7):740-53.
[34] Naz S, Sowers A, Choudhuri R, Wissler M, Gamson J, Mathias A, et al. Abemaciclib, a Selective CDK4/6 Inhibitor, Enhances the Radiosensitivity of Non-Small Cell Lung Cancer In Vitro and In Vivo. Clin Cancer Res. (2018) 24(16):3994-4005.
[35] Johnson DG. Regulation of E2F-1 gene expression by p130 (Rb2) and D-type cyclin kinase activity. Oncogene. (1995) 11(9):1685-92.
[36] Goto Y, Hayashi R, Muramatsu T, Ogawa H, Eguchi I, Oshida Y, et al. JPO1/CDCA7, a novel transcription factor E2F1-induced protein, possesses intrinsic transcriptional regulator activity. Biochim Biophys Acta. (2006) 1759(1-2):60-8.
[37] Mebratu Y, Tesfaigzi Y. How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? Cell Cycle. 2009;8(8):1168-75.
[38] Tomiyama A, Tachibana K, Suzuki K, Seino S, Sunayama J, Matsuda KI, et al. MEK-ERK-dependent multiple caspase activation by mitochondrial proapoptotic Bcl-2 family proteins is essential for heavy ion irradiation-induced glioma cell death. Cell Death Dis. 2010;1(7): e60.
[39] Blumenschein GR Jr, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, , et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol. 2009;27(26):4274-80.
[40] Xie C, Pan Y, Hao F, Gao Y, Liu Z, Zhang X, et al. C-Myc participates in β-catenin-mediated drug resistance in A549/DDP lung adenocarcinoma cells. APMIS. 2014;122(12):1251-8.